Recent meta-analyses [25] have showed substantial benefits of SGLT2 inhibitors, including a reduction in HHF and a slowing of chronic kidney disease progression in older adults, with or without T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.